Other OTC - Delayed Quote USD

Pharma-Bio Serv, Inc. (PBSV)

0.7000 0.0000 (0.00%)
At close: April 22 at 3:35 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
10/31/2023
10/31/2022
10/31/2021
10/31/2020
Total Revenue
15,118.6870
16,976.8560
19,398.7270
20,115.1750
21,564.3600
Cost of Revenue
10,756.8230
11,910.4450
14,517.2790
14,755.2120
14,897.6380
Gross Profit
4,361.8640
5,066.4110
4,881.4480
5,359.9630
6,666.7220
Operating Expense
4,011.3850
3,949.0000
3,706.5030
9,213.6570
4,441.1750
Operating Income
350.4790
1,117.4110
1,174.9450
-3,853.6940
2,225.5470
Other Income Expense
504.0600
570.0760
13.4180
1,977.7000
64.4630
Pretax Income
854.5390
1,687.4870
1,188.3630
-1,875.9940
2,290.0100
Tax Provision
241.5100
377.3070
181.6790
213.2460
239.0880
Net Income Common Stockholders
613.0290
1,310.1800
1,006.6840
-2,089.2400
2,050.9220
Diluted NI Available to Com Stockholders
613.0290
1,310.1800
1,006.6840
-2,089.2400
2,050.9220
Basic EPS
0.03
--
0.04
-0.09
0.09
Diluted EPS
0.03
--
0.04
-0.09
0.09
Basic Average Shares
22,975.2270
--
23,002.5830
23,026.2600
23,003.3270
Diluted Average Shares
23,005.0080
--
23,031.8150
23,161.7270
23,040.0750
Total Operating Income as Reported
350.4790
1,117.4110
1,174.9450
-3,853.6940
2,225.5470
Total Expenses
14,768.2080
15,859.4450
18,223.7820
23,968.8690
19,338.8130
Net Income from Continuing & Discontinued Operation
613.0290
1,310.1800
1,006.6840
-2,089.2400
2,050.9220
Normalized Income
613.0290
1,310.1800
1,006.6840
-2,089.2400
2,050.9220
EBIT
350.4790
1,117.4110
1,174.9450
-3,853.6940
2,225.5470
EBITDA
538.8190
1,311.7320
1,363.3360
-3,780.9660
2,311.8300
Reconciled Cost of Revenue
10,756.8230
11,910.4450
14,517.2790
14,755.2120
14,897.6380
Reconciled Depreciation
188.3400
194.3210
188.3910
72.7280
86.2830
Net Income from Continuing Operation Net Minority Interest
613.0290
1,310.1800
1,006.6840
-2,089.2400
2,050.9220
Normalized EBITDA
538.8190
1,311.7320
1,363.3360
-3,780.9660
2,311.8300
Tax Rate for Calcs
0.0003
0.0002
0.0002
0.0004
0.0001
10/31/2020 - 5/7/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade